When to decide on testosterone replacement despite dopamine agonist therapy in male prolactinomas?

2024-9-17

Pituitary apoplexy: a comprehensive analysis of 93 cases across functioning and non-functioning pituitary adenomas from a single-center

2024-9-13

Desmopressin dose requirements in patients with permanent arginine vasopressin deficiency: a tertiary center experience

2024-9-12

SARS-CoV-2 infection and vaccination in patients with pituitary diseases: the experience of a Brazilian reference center

2024-9-9

Sleep disruption in patients with active and treated endogenous Cushing’s syndrome

2024-9-9

Natural history of untreated microprolactinomas

2024-9-8

GLP-1 receptor agonists may enhance the effects of desmopressin in individuals with AVP deficiency: a case series and proposed mechanism

2024-9-6

Long COVID and pituitary dysfunctions: a bidirectional relationship?

2024-9-6

Skeletal fragility in pituitary disease: how can we predict fracture risk?

2024-9-6

Cardiovascular risk and glucocorticoids: a Dutch National Registry of growth hormone treatment in adults with growth hormone deficiency analysis

2024-8-31

Is semaglutide a target therapy for acquired hypothalamic obesity?

2024-8-30

Does size really matter? A closer look at the absolute size of growth hormone-secreting pituitary adenomas

2024-8-30

Syndrome of inappropriate antidiuresis/hyponatremia in COVID-19

2024-8-28

Vitamin D in pituitary driven osteopathies

2024-8-24

The comprehensive evaluation of oral and fecal microbiota in patients with acromegaly

2024-8-19

Recovery from hypogonadism in men with prolactinoma treated with dopamine agonists

2024-8-19

“Intrasellar tumor-to-tumor metastasis: A single center experience with a systematic review”

2024-8-14

Semaglutide treatment of hypothalamic obesity – a real-life data study

2024-8-9

Somapacitan-induced reversible lipoatrophy in an adult woman with hypopituitarism

2024-8-9

Pituitary Apoplexy: a re-appraisal of risk factors and best management strategies in the COVID-19 era

2024-8-5

Neuroendocrinology of bone

2024-8-3

Is diabetes with acromegaly for life?

2024-8-1

Diagnostic, therapeutic, and prognostic characteristics of patients with acromegaly according to tumor size at diagnosis

2024-8-1

Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma

2024-8-1

Neuroendocrine challenges and clinical outcomes in men with chronic traumatic brain injury: a cross-sectional study

2024-7-29

The diverging role of O-GlcNAc transferase in corticotroph and somatotroph adenomas

2024-7-27

Precocious puberty, pandemic and beyond

2024-7-26

Craniofacial impact of acromegaly: when muscle ma-sse-tter

2024-7-26

Changes in pituitary adenoma patient presentation and outcomes during the COVID pandemic at a Pituitary Center of Excellence

2024-7-24

Clinical use of [18F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants

2024-7-23

Copeptin after pituitary surgery: is it worth measuring?

2024-7-16

Cushing’s disease and bone

2024-7-15

Outcome of non-functioning ACTH pituitary tumors: silent does not mean indolent

2024-7-12

Development and validation of a novel treatment adherence, satisfaction and knowledge questionnaire (TASK-Q) for adult patients with hypothalamic-pituitary disorders

2024-7-8

Temporal and masseter muscle evaluation by MRI provides information on muscle mass and quality in acromegaly patients

2024-7-5

Impact of medical therapy for hormone-secreting Pituitary tumors on bone

2024-7-5

Pituitary surgery and COVID

2024-7-5

Decreased β-cell volume and insulin secretion but preserved glucose tolerance in a growth hormone insensitive pig model

2024-7-3

Correction: Utility of copeptin in predicting non-pathological postoperative polyuria in patients affected by acromegaly undergoing pituitary neurosurgery

2024-6-28

Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

2024-6-28

Cardiac MRI in acromegaly: looking for a big heart

2024-6-28

Pituitary apoplexy: a systematic review of non-gestational risk factors

2024-6-27

Pituitary tumor centers of excellence (PTCOE): the next border of acromegaly treatment

2024-6-25

Clinicopathological analysis of non-functioning pituitary adenomas (PAs) according to the 2022 WHO classification

2024-6-19

Growth hormone increase by luteinizing hormone-releasing hormone reflects gonadotroph-related characteristics in acromegaly

2024-6-19

The conundrum of differentiating Cushing’s syndrome from non-neoplastic hypercortisolism: a systematic review and meta-analysis

2024-6-18

Vertebral fractures in patients with non-functioning pituitary adenomas - a new frontier?

2024-6-14

Pituitary apoplexy in cushing’s disease: a single center study and systematic literature review

2024-6-8

The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study

2024-6-7

Utility of copeptin in predicting non-pathological postoperative polyuria in patients affected by acromegaly undergoing pituitary neurosurgery

2024-6-7